Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      General Practitioners, Nurses Must Stay Up-to-Date With Cancer Trends

      July 3, 2019
      By Brielle Benyon
      Article

      As the number of cancer diagnoses continues to increase across the United States it is crucial that primary care providers know when to refer patients to oncology teams.

      As the number of cancer diagnoses continues to increase across the United States — due to both improved detection methods and an aging population – it is crucial that primary care providers work with oncology teams, and know when to refer patients there, explained Nabil F. Saba, MD, FACP.

      “The role of primary care physicians and general practitioners is really key,” Saba, director of head and neck oncology at the Winship Cancer Institute, said in a recent interview with Oncology Nursing News. “Educating the general practitioners on the signs of symptoms of cancer is also going to be key in allowing the increased detection of cancer by these providers.”

      For example, Saba explained, patients who have a sore throat that does not resolve, even after a course of antibiotics, should be referred to a head and neck expert or an otolaryngologist. While this symptom might be obvious to an oncologist or oncology nurse, the patient might not be seen by one unless they are referred by their primary care provider.

      “As far as other cancers, go, it’s important for the primary care physician to keep an eye on patients who have symptoms that don’t resolve, specifically patients with a history of smoking or who are current smokers,” Saba said, explaining that they are at a higher risk for developing cancer.

      Additionally, all providers — both in the oncology unit and not – should be aware of certain health-related trends that are occurring across the nation. Saba mentioned that the incidence of oropharynx cancer, which is related to human papillomavirus, is on the rise, and has surpassed the incidence of cervical cancer as the leading HPV-related cancer in the United States.

      According to Saba, the number of oropharynx cancers will continue to increase, particularly in men over the age of 65.

      “Even though we’ve learned over the years that HPV-related cancers tend to involve a younger and healthier segment of the population — which is still true to a certain extent – the projection is that over the next couple of decades, this may not be true,” Saba said. “We need to really be on the lookout and expect this disease to increase in an older segment of the population.”

      When it comes to younger populations, particularly women between the age of 18 and 39, the HPV vaccine is decreasing the number of HPV-related cancers, such as cervical precancers, diagnosed across America.

      However, providers must still be vigilant.

      “I wish I could limit this to one set of symptoms, but I think the take home message from this is that since the population is aging, and cancer is expected to remain with high incidence in this country, primary care physicians will play a major role in trying to detect these cancers as early as possible,” Saba said.

      “Early detection of cancer is paramount to improvement in outcomes. This really applies to the majority of cancers. The earlier you detect the cancer, the earlier you can intervene, and the higher chance of curing the patient.”

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman wearing a patterned shirt in front of a dark blue background
      Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
      3 experts in this video
      3 experts in this video
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Related Content

      Image of a person holding a model of the female reproductive system

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Gina Mauro
      June 13th 2025
      Article

      Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Photo of the FDA building

      FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

      Bridget Hoyt
      June 12th 2025
      Article

      UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.


      Anatomical image of a person with the gastrointestinal tract highlighted

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      Jordyn Sava
      June 12th 2025
      Article

      Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.

      Related Content

      Image of a person holding a model of the female reproductive system

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Gina Mauro
      June 13th 2025
      Article

      Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.


      The Vitals

      What New Cancer Drugs Were Approved in 2023?

      Lindsay Fischer
      January 1st 2024
      Podcast

      In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.


      Graphic that resembles a stamp of approval reading "FDA Approved"

      FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

      Bridget Hoyt
      June 12th 2025
      Article

      The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Photo of the FDA building

      FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

      Bridget Hoyt
      June 12th 2025
      Article

      UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.


      Anatomical image of a person with the gastrointestinal tract highlighted

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      Jordyn Sava
      June 12th 2025
      Article

      Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.